FDA

News

FDA panel backs Ardelyx CKD drug, despite agency concerns

While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having

Sales & Marketing

Inside the colourful history of pharma advertising

Pharma companies employ a variety of tactics to increase brand awareness and promote their products.

News

FDA blocks early filing for ADC drug, signalling tougher sta...

ADC Therapeutics has said it will not seek accelerated approval of its Hodgkin lymphoma drug camidanlumab tesirine (cami) based on phase 2 results, as the FDA will not review it unless a co

News

FDA accepts review of SeresTx BLA for oral microbiome therap...

The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an investigational oral

Views & Analysis

Considerations for Mobile Health Technology Developers: Part...

In Part 1 of this series, general wellness devices and mobile me

News

Illustration of a nerve cell on a colored background with light effects

Relief for Amylyx as FDA clears controversial ALS drug Relyv...

Patient organisations have been celebrating the FDA approval yesterday of Amylyx' amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings tha

FDA panel backs Ardelyx CKD drug, despite agency concerns

Inside the colourful history of pharma advertising

FDA blocks early filing for ADC drug, signalling tougher sta...

FDA accepts review of SeresTx BLA for oral microbiome therap...

Considerations for Mobile Health Technology Developers: Part...

Relief for Amylyx as FDA clears controversial ALS drug Relyv...

Roche, Viking, and Syntis showcase obesity drug candidates

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks